France Remains One of Europe’s Leading Biotech Funding Hubs

The French government is actively supporting the biotechnology sector through the France 2030 plan; it has committed US$7.8 billion (€7 billion) toward health innovation and aims to strengthen biomedical research capacity; support the healthcare industry; make France Europe’s leading country for clinical trials; ensure patients have equal access to care; and provide a faster, simpler route to market for innovations. It also aims to create a predictable economic framework that supports health and industrial sovereignty, promote the industrialization of healthcare products in France, help companies in the sector grow, and establish the Health Innovation Agency to drive and strategically manage health innovation.¹ It has set some ambitious goals to make France one of the leading countries for digital health. It aims to accelerate preparedness for emerging infectious diseases and chemical, biological, radiological and nuclear threats, drive the development of at least five innovative biotherapies by 2030, double jobs in the sector, and see the emergence of one new unicorn and five new biotechs.²

France’s Leading Biotechs Driving Innovation and Strategic Alliances

France is home to several major pharmaceutical companies, including Ipsen, Pierre Fabre, Sanofi, and Servier. It is the European Union’s (EU) second-largest pharmaceutical market, generating around US$72.7 billion (€65 billion) in 2025.³ France ranks fourth in Europe for the number of industrial agreements, with 304 signed between 2021 and 2025, and sixth for average value. In 2025, 20% of companies said they had raised funds, down from 37% in 2024, highlighting the financial challenges. HealthTech companies in France raised US$ 2.6 billion (€2.3 billion) in 2025, 10% less than in 2024. Of this, US$1.2 billion (€1.0 billion) came from venture capital.

As in other European countries, France is experiencing a funding slowdown and a more complex regulatory environment, prompting strategic alliances and acquisitions as companies bolster their product pipeline and expand their global footprint. For instance, Ipsen acquired US-based Kartos Therapeutics and Swiss Memo Therapeutics; Sanofi has forged strategic collaborations with US biotechs EVOQ Therapeutics, Kali Therapeutics, and Owkin, and invested in French Biotech Sensorion, and Servier has partnered with French start-up Kyron.bio. Several French biotech companies are casting their research nets wide; for instance, French biotech Osivax entered into a long-term collaboration with South Korean biopharma company GC Biopharma to develop a next-generation seasonal influenza vaccine, and Transgene entered into an immunotherapy deal with Japanese NEC Corporation. More recently, Enodia Therapeutics announced a US$500 million research collaboration with Pfizer to discover and develop Sec61 inhibitors (Table 1).

What Are Some of France’s Biotechs to Watch Out For?

According to the 2026 France HealthTech Panorama, the country has a mature healthcare ecosystem with nearly 2800 companies. Yet around a third are less than 5 years old, and more than half are very small entities (VSEs) with fewer than 10 employees.However, 10% of the biotech companies in France have commercialized their products, and 27% are in the research and proof-of-concept stage.⁴ Several French biotechs have attracted investor attention over the past 12 months, with Abivax and Nanobiotix closing US$920 million (€807 million) and US$114.4 million (€98.6 million) public offerings, respectively; Axoltis Pharma completed a US$20.9 million (€18 million) and Bionyra Pharma closed a US$165 million Series A funding round, and Cyllene Therapeutics secured €33 million US$38 million) Series C funding (Table 2).

The following are French biotech companies to watch (Table 3).

Abivax develops microRNA-based treatments that target chronic inflammatory diseases, including ulcerative colitis and Crohn’s disease. In July 2026, it raised US$920 million (€807 million) in an expanded share sale to fund late-stage Phase 3 trials of its lead candidate, obefazimod (miR-124), for ulcerative colitis. The company presented Phase 3 ABTECT maintenance and induction data at United European Gastroenterology in September and plans to submit an new drug approval (NDA) application by year-end 2026. Topline results from the Phase 2b ENHANCE-CD induction trial of obefazimod for Crohn’s disease are expected in mid-2027.⁵ Investors and industry executives have long seen Abivax as a potential acquisition target for larger drugmakers seeking to expand their inflammation and immunology businesses.

Axoltis Pharma is developing therapies for neurodegenerative disease, with its lead program aimed at amyotrophic lateral sclerosis (ALS). Axoltis’ core approach focuses on synthetic peptide therapeutics that address upstream disease mechanisms rather than symptom control. The company’s lead candidate NX210c is designed to restore or protect central nervous system function by acting on biological processes linked to neurodegeneration, including blood-brain barrier impairment. In April 2024, Axoltis received authorization from France’s medicines regulator to initiate the SEALS phase 2 study of NX210c in ALS patients, and it released positive top-line results in September 2026.⁶ In December 2025, Axoltis closed a US$20.9 million (€18 million) Series A financing round.⁷ The funding would accelerate development of NX210c in ALS and support broader pipeline activities in neurodegeneration, as well as clinical and operational scale-up.

Bionyra Pharma was founded in 2025 by Sofinnova Partners and Frédéric Marrache, MD, PhD, a former R&D VP at Sanofi. The company develops next-generation biologics for immune-mediated inflammatory diseases. Bionyra licensed the ex-China rights to BYN-001 from New Jersey-based NovaRock Biotherapeutics. According to the company, the monoclonal antibody targets the IL-25 pathway, incorporates half-life extension (HLE) technology, and is at the investigational new drug (IND) application filing stage for atopic dermatitis. Bionyra also licensed 2 TL1A-targeting assets from Chinese biotech TrueLab Biopharmaceutical. BYN-002 is an anti-TL1A monoclonal antibody with HLE technology for patients with IBD and other TL1A-relevant indications. Positive interim Phase 1 results in healthy volunteers were released in October 2026.⁸ BYN-003 is a TL1AxIL-23p19 bispecific antibody with HLE technology that began a Phase 1 study in healthy volunteers in April 2026. The company completed a US$165 million (€143 million) Series A funding round to support asset development, with Sanofi as an investor.⁹

Cyllene Therapeutics (formerly EG 427) is a privately held French biotechnology company developing gene therapies for chronic disorders of the peripheral and central nervous systems. Philippe Chambon, François Giuliano, and Alberto Epstein founded it in 2019. It completed a US$38.3 million (€33 million) Series C funding round to support its proprietary HERMES technology, non-replicating herpes simplex virus type 1 vectors, for local rather than systemic injection.¹⁰ Its lead candidate, EG110A, is in a first-in-human Phase 1/2 study for neurogenic detrusor overactivity (ND) and urinary incontinence following spinal cord injury or multiple sclerosis. The US FDA has granted EG110A Regenerative Medicine Advanced Therapy (RMAT) designation.¹¹

Enodia Therapeutics is a biotechnology start-up that develops best-in-class small-molecule therapies for targeted protein degradation (TPD). Based on pioneering research from the Institut Pasteur and built by Argobio Studio, the company’s proprietary platform targets the Sec61 translocon to degrade disease-driving proteins linked to inflammation, immunology, and oncology. Enodia raised a US$25 million (€20.7 million) seed round in January 2026, co-led by Elaia, Pfizer Ventures, and Bpifrance through its InnoBio strategy.¹² The company is advancing programs in cancer, inflammatory and autoimmune disease, and viral infection. In October 2026, Enodia announced a research collaboration with Pfizer to develop Sec61-targeting small molecules. Enodia will receive an upfront payment, milestone payments, and tiered royalties, with a potential total value of more than $500 million.¹³

Innate Pharma SA is an immuno-oncology biotech developing antibodies that target innate immune pathways, including natural killer cells and immune checkpoints. The company’s strategy combines proprietary development in rare hematological cancers and out-licensing to larger partners in adjacent disease areas. It licensed monalizumab, an anti-NKG2A antibody, to AstraZeneca in October 2018 through a co-development and commercialization agreement initiated in 2015. Monalizumab is currently in the pivotal PACIFIC-9 Phase 3 trial in combination with durvalumab for patients with stage 3 non-small cell lung cancer.¹⁴ In August 2026, Innate Pharma entered a strategic partnership with Sobi to license lacutamab in T-cell lymphoma, triggering a US$75 million upfront payment and initiating the TELLOMAK-3 confirmatory Phase 3 study expected in Q1 2027.¹⁵

Kyron.bio pioneers precision glycosylation control in antibody therapeutics to improve efficacy. Its proprietary cell-based systems and structure-guided design harness N-glycans to develop treatments for cancer and autoimmune diseases. Founded in 2022, the company commercializes technology developed by founder and CEO Emilia McLaughlin through France’s Entrepreneur First Program and attracted US$5.6 million (€5.5 million) in seed funding in May 2025.¹⁶ Kyron.bio partners with pharmaceutical companies including Servier to apply its patented glycoengineering technology to next-generation antibodies while developing an in-house therapeutics portfolio.¹⁷

Nanobiotix, founded in 2003 as a spin-off from the State University of New York at Buffalo, is a Paris-based biotechnology company developing nanomedicine therapies to enhance cancer treatment, particularly radiotherapy. Founded on research by Laurent Levy, it went public on Euronext Paris in 2012 and later listed on Nasdaq, raising about US$12.3 million (€11 million) across funding rounds. In May 2026, it completed a US$ 96.2 million (€86.1 million) follow-on offering to advance other platforms. Its lead candidate, co-developed with Janssen Pharmaceutical Companies of Johnson & Johnson, is a radiotherapy-activated JNJ-1900 (NBTXR3) comprising functionalized hafnium oxide nanoparticles, being studied alone or in combination across solid tumors. At the 2026 ESTRO meeting, the company presented positive Part 1 data from the J&J-sponsored Phase 2 CONVERGE study in patients with Stage 3 inoperable non-small cell lung cancer (NSCLC). The FDA accepted a protocol amendment to the ongoing, J&J-sponsored pivotal NANORAY-312 study in head and neck cancer patients, removing the interim analysis and revising the final analysis to require fewer events and occur sooner.¹⁸

Paris-based agentic AI company Owkin was co-founded in 2016 by Thomas Clozel, a clinical research physician and former assistant professor of clinical hematology, and machine-learning academic Gilles Wainrib. It became a unicorn in November 2021 following a US$180 million equity investment from Sanofi. Since then, Owkin has raised more than US$300 million from investors including Google Ventures, Otium Capital, and MACSF. Owkin developed MOSAIC (Multi-Omics Spatial Atlas in Cancer), a multimodal patient-data network supporting its small clinical-stage oncology program. Its lead and only disclosed clinical drug candidate, OKN4395, is a first-in-class selective inhibitor of EP2, EP4, and DP1 prostanoid receptors, targeting immunosuppressive signaling in the microenvironment of advanced solid tumors. The company licenses its K Pro AI Scientist platform to pharmaceutical companies for R&D. In 2026, it signed 3-year K Pro agreements with AstraZeneca in May 2026 for competitive intelligence and decision support, Sanofi in June 2026 for drug research across multiple therapies, and Boehringer Ingelheim in September 2026 for oncology and immunology, following a 2025 pilot and with Servier in September 2026 to advance its oncology research.^19-22

Founded in 2017 as an IMAXIO spin-off, Osivax was co-founded by Alexandre Levert, Florence Nicolas, and Fergal Hill. It uses its proprietary oligoDOM nanoparticle technology to develop vaccines that elicit both T-cell and B-cell immune responses. Osivax has raised US$42.2 million from investors, including Noshaq and the EIC Fund. In October 2026, its lead candidate, OVX836, which targets influenza nucleoprotein, failed as a standalone vaccine in a trial.²³ Osivax now plans to develop OVX836 only in combination with established seasonal vaccines, through partnerships with GC Biopharma and an undisclosed global pharmaceutical company.²⁴

Sensorion is a clinical-stage biotech developing therapies to restore hearing and treat or prevent hearing loss. Its R&D platform deepens understanding of inner-ear diseases and supports identifying drug targets and mechanisms of action. Its lead gene therapy program, SENS-601 (GJB2-GT), targets hearing loss caused by GJB2 mutations in adults and children. The program is being developed through a strategic collaboration with Institut Pasteur, which focuses on hearing genetics. Sensorion plans to submit a US IND application for SENS-601 by the end of 2026 and dose the first patient in the SENS-601 HearConnex trial by early 2027.²⁵ Sensorion’s pipeline also includes SENS-401 (arazasetron), a clinical-stage small molecule studied in 3 Phase 2 trials: cisplatin-induced ototoxicity, with analysis completed in Q1 2026; preservation of residual hearing in patients undergoing cochlear implantation, completed in 2024 with Cochlear Limited; and sudden sensorineural hearing loss, completed in 2022. In January 2026, the company completed a €60 million financing, including a €20 million investment from Sanofi and support from existing investors Redmile Group, Artal, advised by Invus, and Sofinnova Partners. The funds will support the SENS-601 IND and the continued clinical advancement of SENS-501.^26.

Future Opportunities for Investment in France’s Biotech Industry

France is home to Sanofi, one of the world’s largest European pharmaceutical companies; bioMérieux, a global in vitro diagnostics leader; renowned research institutes Pasteur and Curie; and biotech startups Bionyra Pharma and Enodia Therapeutics. The France 2030 plan will boost funding for health and biotherapy, recognizing that the country’s strengths in biology, immunology, and genomics remain under-commercialized. With targeted capital, clinical-trial infrastructure and manufacturing investment, France could become Europe’s leading biopharmaceutical innovation hub, not just a research nation whose discoveries are commercialized elsewhere.

References

1. Health Innovation 2030: a €7 billion plan for research. Le Pôle Biologie. Médecine. Santé (BMS). Accessed November 3, 2026. https://bms.univ-lorraine.fr/en/news/health-innovation-2030-eu7-billion-plan-research
2. Strategic Council for the Healthcare Industries (CSIS) Government. Healthcare Innovation 2030. June 29, 2021. https://www.elysee.fr/admin/upload/default/0001/10/878189f8b95f7905f5b4ecf540701a425e615cdf.pdf
3. Viola France Healthcare & Life Sciences Industry Report 2026. Pharma Boardroom. March 2026. https://pharmaboardroom.com/country-reports/healthcare-life-sciences-review-france-2026/
4. Panorama France HealthTech 2026: a mature, innovative and resilient sector facing a more demanding environment. March 23, 2026. https://france-biotech.fr/wp-content/uploads/2026/03/France_Biotech_PR_Panorama_France_HealthTech_2026_VDEF.pdf
5. Abivax announces closing of $920 million public offering. News release. Abivax. July 6, 2026. Accessed November 3, 2026. https://ir.abivax.com/news-releases/news-release-details/abivax-announces-closing-920-million-public-offering
6. Axoltis Pharma announces topline Phase 2 results for NX210c in Amyotrophic Lateral Sclerosis. News release. Axoltis. September 15, 2026. Accessed November 3, 2026. https://www.axoltis.com/2026/09/15/axoltis-pharma-announces-topline-phase-2-results-for-nx210c-in-amyotrophic-lateral-sclerosis/
7. Axoltis Pharma raises €18 million to accelerate development of Amyotrophic Lateral Sclerosis (ALS) drug candidate. News release. Axoltis. December 2, 2025. Accessed November 3, 2026. 251202-Axoltis-Pharma-funding-EN.pdf
8. Bionyra Pharma Announces Positive Interim Phase 1 Results for BYN-002, a Long-Acting Anti-TL1A Antibody. News release. Bionyra Pharma. October 20, 2026. Accessed November 3, 2026. https://bionyra.com/bionyra-pharma-announces-positive-interim-phase-1-results-for-byn-002/
9. Thomas. Backed by $165M, Bionyra Pharma launches to advance inflammatory disease biologics. GENE. June 26, 2026.https://bionyra.com/gen-backed-by-165m-bionyra-pharma-launches-to-advance-inflammatory-disease-biologics-test-post/
10. Cyllene Therapeutics (formerly known as EG 427) raises €33 million Series C financing to advance clinical development of EG110A and pipeline expansion. News release. July 7, 2026. Accessed November 3, 2026. https://cyllene-tx.com/Cyllene-Therapeutics-formerly-known-as-EG-427-Raises-%E2%82%AC33-Million-Series-C-Financing-to-Advance-Clinical-Development-of-EG110A-and-Pipeline-Expansion.html
11. Cyllene Therapeutics receives US FDA regenerative medicine advanced therapy (RMAT) designation for EG110A in neurogenic detrusor overactivity (NDO). News release. Cyllene Therapeutics. September 14, 2026. Accessed November 3, 2026.https://cyllene-tx.com/Cyllene-Therapeutics-Receives-U-S--FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-EG110A-in-Neurogenic-Detrusor-Overactivity-NDO-.html
12. Enodia Therapeutics secures €20.7M to advance a small molecule platform. News release. Enodia Therapeutics. January 8, 2026. Accessed November 3, 2026.https://www.enodiatx.com/enodia-therapeutics-secures-20m/
13. Enodia Therapeutics announces research collaboration and license agreement with Pfizer to develop Sec61-targeting small molecules. News release. Enodia Therapeutics. October 13, 2026. Accessed November 3, 2026.https://www.enodiatx.com/enodia-therapeutics-announces-research-collaboration-and-license-agreement-with-pfizer-to-develop-sec61-targeting-small-molecules/
14. Innate Pharma: PACIFIC-9 phase 3 trial readout timing updated to H1 2027. News release Innate Pharma. October 27, 2026. Accessed November 3, 2026. https://www.innate-pharma.com/media/all-press-releases/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-h1-2027
15. Innate and Sobi announce partnership is now effective following completion of closing conditions. News release. Innate Pharma. September 16, 2026. Accessed November 3, 2026. https://www.innate-pharma.com/media/all-press-releases/innate-and-sobi-announce-partnership-now-effective-following-completion-closing-conditions
16. Kyron.bio today announced a €5.5M seed round. News release. Kyron.bio. May 28, 2025. Accessed November 3, 2026. https://kyron.bio/news-stories/kyron-bio-today-announced-a-eu5-5m-seed-round
17. Kyron.bio announces strategic partnership with Servier to advance precision glycosylation in antibody therapeutics. News release. Kyron.bio. March 9, 2025.Accessed November 3, 2026. https://kyron.bio/news-stories/kyron-bio-announces-strategic-partnership-with-servier-to-advance-precision-glycosylation-in-antibody-therapeutics
18. Nanobiotix provides first quarter 2026 operational and financial update. News release. Nanobiotix. June 2, 2026. Accessed November 3, 2026. https://ir.nanobiotix.com/news-releases/news-release-details/nanobiotix-provides-first-quarter-2026-operational-and-financial
19. Owkin to build AI agents as part of a multi-year K Pro license agreement with AstraZeneca. News releases. Owkin. May 13, 2026. Accessed November 3, 2026. https://www.owkin.com/newsfeed/owkin-to-build-ai-agents-as-part-of-a-multi-year-k-pro-license-agreement-with-astrazeneca
20. Owkin to build AI agents as part of a multi-year K Pro collaboration with Sanofi. News release. Owkin. June 5, 2026. Accessed November 3, 2026. https://www.owkin.com/newsfeed/owkin-to-build-ai-agents-as-part-of-a-multi-year-k-pro-collaboration-with-sanofi
21. Owkin to license K Pro AI scientist and multimodal oncology and immunology data to Boehringer Ingelheim. News release. Owkin. September 2, 2026. Accessed November 3, 2026. https://www.owkin.com/newsfeed/owkin-to-license-k-pro-ai-scientist-and-multimodal-oncology-and-immunology-data-to-boehringer-ingelheim
22. Owkin to license K Pro and multimodal data to servier to advance oncology research. News release. Owkin. September 11, 2026. Accessed November 3, 2026. https://www.owkin.com/newsfeed/owkin-to-license-k-pro-and-multimodal-data-to-servier-to-advance-oncology-research
23. Osivax reports Phase 2b results for OVX836 and advances combination strategy for next-generation seasonal influenza vaccines. News release. Osivax. October 15, 2026. Accessed November 3, 2026. https://osivax.com/osivax-reports-phase-2b-results-for-ovx836-and-advances-combination-strategy-for-next-generation-seasonal-influenza-vaccines/
24. Osivax and GC Biopharma enter strategic collaboration to develop a next-generation influenza vaccine. News release. Osivax. August 27, 2026. Accessed November 3, 2026. https://osivax.com/osivax-and-gc-biopharma-enter-strategic-collaboration-to-develop-a-next-generation-influenza-vaccine/
25. Sensorion reports 2026 half-year results, provides corporate update and announces availability of half-year report. News releases. Sensorion. September 23, 2026. Accessed November 3, 2026. https://sensorion2021tf.q4web.com/English/news/news-details/2026/Sensorion-Reports-2026-Half-Year-Results-Provides-Corporate-Update-and-Announces-Availability-of-Half-Year-Report/default.aspx
26. Sensorion announces €60 million financing with a €20M strategic investment from Sanofi and support from global healthcare specialists to advance genetic medicine pipeline. News release. Sensorion. January 28, 2026. Accessed November 3, 2026. https://www.sensorion.com/en/category/press-releases/